ArticleCase reports in endocrinology2026
Alemtuzumab-Induced Graves' Disease Complicated by Pretibial Myxoedema: A Case Report.
Article in Case reports in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Alemtuzumab-Induced Graves' Disease Complicated by Pretibial Myxoedema: A Case Report.Case reports in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alemtuzumab, a monoclonal antibody targeting CD52, is associated with a high incidence of secondary autoimmune disease, most commonly thyroid dysfunction. Alemtuzumab-induced Graves' disease (AIGD) typically follows a relapsing course and may exhibit atypical or severe phenotypes during immune reconstitution (IR). Case Presentation: We report a case of severe thyrotoxicosis following alemtuzumab therapy for multiple sclerosis, complicated by the development of thyroid eye disease (TED) and pretibial myxoedema (PTM). Despite escalation of antithyroid therapy, biochemical and clinical control remained suboptimal. Radioiodine therapy was not pursued due to the presence of established orbitopathy. Given persistent severe disease and extrathyroidal manifestations, definitive management with total thyroidectomy was undertaken. Results: Thyroidectomy resulted in rapid biochemical control of thyrotoxicosis. thyroid-stimulating hormone-receptor antibody (TRAb) remained markedly elevated after thyroidectomy, indicating persistent autoimmune activity despite removal of the thyroid gland. Conclusion: This case highlights an aggressive and uncommon presentation of AIGD characterised by severe thyrotoxicosis, orbitopathy and PTM. Clinicians should recognise the potential for atypical and refractory disease following alemtuzumab therapy. In selected cases, early consideration of definitive therapy is warranted, particularly when radioiodine is considered unsuitable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.